PMEF
TGTX icon

Point72 Middle East FZE’s TG Therapeutics TGTX Stock Holding History

Point72 Middle East FZE’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-233,978
Closed -$5.81M – 1868
2023
Q2 		$5.81M Buy
233,978
+220,684
+1,660% +$5.7M 0.16% 157
2023
Q1 		$200K Buy
+13,294
New +$202K 0.01% 952

Other funds holding TGTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Point72 Middle East FZE's TGTX Position: Q3 2023 in Review

Point72 Middle East FZE sold out of TG Therapeutics (TGTX) in Q3 2023, closing a stake of 233,978 shares — an estimated $5.81M sold.

Point72 Middle East FZE first reported a position in TGTX in Q1 2023 and held it in 2 quarters. The position peaked at $5.81M in Q2 2023. 236 funds tracked by Wall St. Rank hold TGTX as of Q3 2023.

  • Point72 Middle East FZE reported no remaining TG Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Point72 Middle East FZE sold 233,978 TG Therapeutics shares in Q3 2023, an estimated $5.81M.
  • Point72 Middle East FZE first reported a position in TG Therapeutics in Q1 2023 and held it in 2 quarters.
  • Point72 Middle East FZE's TG Therapeutics position peaked at $5.81M in Q2 2023.
  • 236 funds tracked by Wall St. Rank held TG Therapeutics as of Q3 2023.

Based on Point72 Middle East FZE's 13F filing for Q3 2023, filed 14 Nov 2023.